Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study

    AMSTERDAM, Jan. 31 /CNW/ - Oncology focused biopharmaceutical product
development company Kiadis Pharma announced today that it has successfully
finalized its Rhitol(TM) Phase II clinical trial with the last patient
completing its six month treatment cycle. Rhitol(TM) is evaluated as treatment
for patients with extensive chronic Graft versus Host Disease (GvHD)
intolerant or resistant to standard immunosuppressive treatment.
    The current preliminary clinical results demonstrate an excellent safety
profile for Rhitol(TM) and evidence of efficacy in the alleviation of the
symptoms associated with chronic Graft versus Host Disease. After this
clinical study was closed for enrollment mid 2007 Kiadis Pharma allowed new
patients to be treated under a compassionate protocol. The successful
completion of the Phase II clinical trial of Rhitol(TM) paves the way for a
phase III study and Kiadis Pharma is planning to file for a phase III multi
center clinical trial in the USA and Canada within the next few months.
    Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the
positive outcome of this study and the potential shown by Rhitol(TM). This
product would fulfill a significant unmet medical need since patients with
chronic GvHD resistant or intolerant to immunosuppressive drugs have no other
standard treatment option available to them and this disease can subsequently
develop into a life-threatening condition."
    To read the complete press releases please go to

    English release is provided by Kiadis Pharma. Equivalent translations are
from a third party.

For further information:

For further information: Kiadis Pharma B.V., Eefje Simpelaar, Director
Communications, Email:, Tel: +31-20-8884815, Mob

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890